Solana Company (NASDAQ:HSDT) Sees Large Decline in Short Interest
by Scott Moore · The Cerbat GemSolana Company (NASDAQ:HSDT – Get Free Report) saw a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 1,010,452 shares, a drop of 25.8% from the February 12th total of 1,361,910 shares. Based on an average daily trading volume, of 369,148 shares, the short-interest ratio is presently 2.7 days. Approximately 3.0% of the shares of the company are sold short. Approximately 3.0% of the shares of the company are sold short. Based on an average daily trading volume, of 369,148 shares, the short-interest ratio is presently 2.7 days.
Institutional Investors Weigh In On Solana
A number of large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD bought a new position in shares of Solana in the 4th quarter worth approximately $46,000. Grant Private Wealth Management Inc bought a new stake in Solana during the fourth quarter valued at approximately $46,000. OMERS ADMINISTRATION Corp bought a new stake in Solana during the fourth quarter valued at approximately $88,000. Aristides Capital LLC purchased a new stake in Solana during the fourth quarter valued at approximately $137,000. Finally, XTX Topco Ltd bought a new position in Solana in the 4th quarter worth $140,000. 18.63% of the stock is currently owned by institutional investors.
Solana Stock Performance
Shares of HSDT stock traded up $0.02 on Friday, reaching $2.11. The stock had a trading volume of 131,457 shares, compared to its average volume of 393,746. The stock has a market cap of $87.14 million, a P/E ratio of 0.00 and a beta of 1.07. Solana has a 1 year low of $1.74 and a 1 year high of $366.68. The company has a 50 day simple moving average of $2.53 and a 200 day simple moving average of $6.00.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on HSDT shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Solana in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Solana from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Report on HSDT
About Solana
Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.
The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.